Therapeutics based on RNAi (RNA interference) offer the potential to treat a number of ailments. Additionally, RNA interference (RNAi) has promise for the treatment of viral illnesses such hepatitis C virus (HCV) and human immunodeficiency virus (HIV) (HIV). Furthermore, RNAi is now frequently used in biological and biomedical research to examine the impact of preventing the expression of a particular gene. It is thought to be a highly specific method for gene silencing and has enormous potential for the treatment of numerous pathologic conditions, including cancer, viral infections, and cardiovascular diseases, among others.
Market Statistics
By the end of 2022, the market for RNAi technology is anticipated to be worth US$ 1,963.2 million.
To Get More Business Strategies Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/5281
Drivers
During the projected period, an increased focus on the development of RNAi therapies (RNAi-based treatments having the potential to treat a range of ailments) is anticipated to fuel the growth of the worldwide RNAi technology market. For instance, industry participants are spending a lot of money developing therapeutic RNAi. The Phase I clinical trial for the Company’s siRNA (small interfering RNA) therapeutic candidate, STP707, with intravenous (IV) administration in the United States for the treatment of solid tumours will begin in February 2022, according to a press release from Sirnaomics Ltd.
Opportunities
Global RNAi technology market participants should have significant growth prospects due to the rising incidence of cancer. For instance, the demand for efficient cancer therapies is rising quickly in tandem with the rising prevalence of cancer among the world’s population. One of the biggest health issues in the globe is cancer. The World Health Organization (WHO) reports that cancer was the biggest cause of death globally in 2020, accounting for close to 10 million deaths, or close to one in every six. In order to produce innovative (RNAi-based) cancer treatments and therapies, numerous pharmaceutical and biotechnology companies are making significant investments in research and development.
Restraints
The development of the worldwide RNAi technology market is anticipated to be hampered by strict laws and regulations as well as the unstable and potentially immunogenic nature of RNA. For instance, RNA-based treatments require unique delivery methods or chemical alterations to enable them to reach the minimal effective concentration due to the intrinsic instability of RNA. Furthermore, due to its immunogenicity and labile nature, mRNA cannot be used in therapeutic settings. In consequence, it is anticipated that this will impede market expansion. As a result, it is anticipated that the global market for RNAi technology will experience slow growth.
Impact
The COVID-19 (pandemic) outbreak is anticipated to have a substantial effect on market expansion. Therapeutics for COVID-19 are being created with the help of RNAi technology. RNAi against COVID-19 illness may be targeted at one or both of two different types of targets, such as viral proteins required for the survival and reproduction of SARS-CoV-2 and host components involved in the virus’s entry into and movement through cells. Additionally, three siRNA products have been given the thumbs-up by the U.S. Food and Drug Administration (FDA) for use in humans, raising great hopes for siRNA therapies for coronaviruses. The market for RNAi technology is then anticipated to grow as a result.
Key Takeaways
The market for RNAi technology was valued at US$ 1,783.5 Mn in 2021 and is anticipated to grow at a CAGR of 10.1% from 2022 to 2028 to reach US$ 3,506.5 Mn.
Inquire More Or Share Questions If Any Before The Purchase On This Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/5281
With a 98.5% market share in terms of value, the medication discovery and development application segment dominated the global RNAi technology market in 2021. Increasing product approval and launches are anticipated to fuel the segment’s expansion throughout the course of the forecast year.
Market Trends
As long as there is any clinical experience with long-term RNAi-based medicines, the potential for RNAi-based therapeutics is limitless. Globally, RNA-based medicinal research and development (R&D) activities are expanding as a result of abundant research funding, supportive governmental policies, and extensive R&D infrastructure. Throughout the projection period, it is anticipated that this tendency would persist, fueling market expansion.
Competitive Landscape
Thermo Fisher Scientific Inc., QIAGEN, Alnylam Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., SBI Biotech Co. Ltd., Ohio Pharmaceuticals Corp., Silence Therapeutics PLC, Arcturus Therapeutics, Benitec Biopharma Ltd., Ionis Pharmaceuticals Inc., and Sigma Aldrich are a few of the major companies active in the global RNAi technology market.
Recent Developments
A definitive deal between Thermo Fisher Scientific and Brammer Bio was signed in March 2019. As per this agreement, Thermo Fisher would buy Brammer Bio for USD 1.7 billion in cash.
A novel, investigational RNA interference (RNAi) therapy for the treatment of chronic hepatitis B virus (HBV) infection was introduced in November 2018 by Vir Biotechnology Inc. and Alnylam Pharmaceuticals Inc.
Purchase This Premium Report @ https://www.coherentmarketinsights.com/insight/buy-now/5281
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Application
- Market Snapshot, By Geography
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing approvals for RNAi therapeutics
- Stringent rules and regulations
- The outbreak of COVID-19 (pandemic)
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER’s Analysis
- Merger and Acquisition Scenario
- Market Dynamics
- Global RNAi Technology Market – Impact of Coronavirus (Covid-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
- Global RNAi Technology Market, By Application, 2017-2028, (US$ Mn)
- Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 – 2028
- Segment Trends
- Drug Discovery and Development
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
- Therapeutics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017-2028,(US$ Mn)
- Introduction
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:
Mr. Shah
Coherent Market Insights Pvt Ltd,
533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States
Email: sales@coherentmarketinsights.com
Phone: U.S.: +1-206-701-6702
U.K.: +44-020-8133-4027
JAPAN: +81-50-5539-1737
INDIA: +91-848-285-0837